Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study

Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study

Abstract Background Bone metastases are frequently observed in advanced cancer, and bone modifying agents are used to prevent or treat skeletal-related events. Zoledronic acid is contraindicated in patients with severe renal impairment (Ccr < 30 mL/min), but it is not completely known whether den...

Full description

Bibliographic Details
Main Authors: Kazuyo Nakamura, Michihiro Kaya, Yuki Yanagisawa, Keisuke Yamamoto, Nana Takayashiki, Hirotoshi Ukita, Mariko Nagura, Kaori Sugiue, Mariko Kitajima, Kumi Hirano, Hiroki Ishida, Chiharu Onoda, Yutaka Kobayashi, Eiji Nakatani, Keiichi Odagiri, Takaya Suzuki
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Denosumab
Bone metastases
Renal insufficiency
Hypocalcemia
Online Access:https://doi.org/10.1186/s12885-024-11942-2

Internet

https://doi.org/10.1186/s12885-024-11942-2

Similar Items